Hepatitis C virus genotype 4: Genotype 1's little brother. Issue 1 (1st December 2016)

• Record Type: Journal Article
• Authors: Llaneras, J.; Riveiro‐Barciela, M.; Buti, M.; Esteban, R.
• Is Part Of: Journal of viral hepatitis. Volume 24:Issue 1(2017)
• Page Start: 4
• Page End: 12
• Publication Date: 2016-12-01
• Subjects: daclatasvir -- genotype 4 -- hepatitis C -- ledipasvir -- simeprevir -- sofosbuvir; Hepatitis, Viral -- Periodicals; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; 616.3623
• DOI: 10.1111/jvh.12620
• Languages: English
• ISSNs: 1352-0504

Abstract

Summary: Treatment for hepatitis C virus genotype 4 infection has undergone a major advance over the past 5 years with the emergence of direct‐acting antiviral agents. Previously, genotype 4 treatment had been limited to the combination of pegylated interferon and ribavirin, with low rates of sustained virological response. The combinations of new direct‐acting agents have resulted in a radical improvement in hepatitis C therapy. Much of the currently available efficacy and safety information in the treatment of genotype 4 has been extrapolated through the results of genotype 1. In this report, we review the efficacy and safety data obtained in recent studies focusing on genotype 4 patients, including special populations, such as those with decompensated cirrhosis.